Key terms
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OCUL news
Yesterday
4:22pm ET
Ocular Therapeutix Announces New Leadership and Incentive Plan Expansion
Apr 17
5:10am ET
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
Apr 16
7:13am ET
Ocular Therapeutix announces appointments of CMO, CDO
Apr 16
12:30am ET
Analysts Are Bullish on Top Healthcare Stocks: OptimizeRx (OPRX), Ocular Therapeutix (OCUL)
Apr 15
7:04am ET
Ocular Therapeutix appoints Dugel as President, CEO
Apr 08
6:37am ET
Ocular Therapeutix (OCUL) Gets a Buy from Piper Sandler
Apr 08
6:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
Apr 07
6:15pm ET
Buy Rating Affirmed: Paxtrava’s Promising Efficacy and Safety Profile in Glaucoma Treatment
Apr 07
6:29am ET
Ocular Therapeutix announces Phase 2 PAXTRAVA glaucoma data
Mar 25
4:43pm ET
Ocular Therapeutix files to sell 43.22M shares of common stock for holders
Mar 13
6:16am ET
Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects
Mar 13
6:10am ET
Ocular Therapeutix price target raised to $15 from $12 at H.C. Wainwright
Mar 13
2:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
Mar 12
7:25am ET
Ocular Therapeutix price target raised to $11 from $8 at TD Cowen
Mar 12
6:18am ET
Ocular Therapeutix price target raised to $24 from $12 at JMP Securities
Mar 12
5:20am ET
Buy Rating Affirmed for Ocular Therapeutix on Strong Financials and Promising Pipeline Developments
Mar 12
12:35am ET
Buy Rating Affirmed for Ocular Therapeutix on Strong Phase 3 Results and Strategic Focus
Mar 11
7:35pm ET
Balanced Outlook: Hold Rating on Ocular Therapeutix Amidst Trial Progress and Management Changes
Mar 11
4:23pm ET
Ocular Therapeutix reports Q4 EPS (35c), consensus (30c)
Mar 11
2:04pm ET
Ocular Therapeutix options imply 11.5% move in share price post-earnings
Mar 11
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 11, 2024
Mar 04
2:04pm ET
Ocular Therapeutix options imply 8.8% move in share price post-earnings
Feb 26
7:35am ET
Ocular Therapeutix price target raised to $15 from $10 at Piper Sandler
Feb 25
11:37pm ET
Ocular Therapeutix Poised for Growth with Strategic Leadership Hires and Strong Financial Position
Feb 23
5:19am ET
Strategic Leadership and Strong Financials Bolster Buy Rating for Ocular Therapeutix
Feb 22
7:54am ET
Ocular Therapeutix Raises $325M in Strategic Equity Financing
Feb 22
7:52am ET
Ocular Therapeutix reports inducement grants under Nasdaq listing rule
Feb 22
7:49am ET
Ocular Therapeutix announces board of directors, leadership changes
Feb 22
7:46am ET
Ocular Therapeutix sells 32.4M shares at $7.52 in private placement
Feb 15
8:06am ET
Ocular Therapeutix appoints Meyers to Chief Commercial Officer
Feb 13
9:35am ET
Buy Recommendation for Ocular Therapeutix on Positive SOL Trial Amendments and Strong Pipeline Positioning
No recent press releases are available for OCUL
OCUL Financials
Key terms
Ad Feedback
OCUL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OCUL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range